NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $29.43 +0.53 (+1.83%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harmony Biosciences Stock (NASDAQ:HRMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$28.85▼$29.5150-Day Range$27.94▼$39.0952-Week Range$26.47▼$41.61Volume399,313 shsAverage Volume576,857 shsMarket Capitalization$1.69 billionP/E Ratio13.95Dividend YieldN/APrice Target$53.33Consensus RatingBuy Company OverviewHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More… Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 92% of companies evaluated by MarketBeat, and ranked 112th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHarmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth27.98% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 13.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 13.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.25.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.47. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.02% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 15.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.02% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 15.09%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.22 News SentimentHarmony Biosciences has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Harmony Biosciences this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $619,167.00 in company stock.Percentage Held by Insiders23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Stock News HeadlinesFirst Week of June 20th Options Trading For Harmony Biosciences Holdings (HRMY)April 24 at 12:06 AM | nasdaq.comHarmony Biosciences price target lowered to $32 from $33 at BofAApril 22 at 1:46 AM | markets.businessinsider.com[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.April 24, 2025 | Colonial Metals (Ad)Bank of America Securities Sticks to Its Sell Rating for Harmony Biosciences Holdings (HRMY)April 22 at 1:46 AM | markets.businessinsider.com6HRMY : Breaking Down Harmony Biosciences...April 8, 2025 | benzinga.comHarmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X SyndromeApril 8, 2025 | finance.yahoo.comHarmony Biosciences Appoints Ron Philip to Board of DirectorsApril 8, 2025 | msn.comHarmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of DirectorsApril 3, 2025 | businesswire.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $34.41 at the beginning of 2025. Since then, HRMY shares have decreased by 14.5% and is now trading at $29.43. View the best growth stocks for 2025 here. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) posted its earnings results on Tuesday, February, 25th. The company reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. The firm's revenue for the quarter was up 19.5% on a year-over-year basis. Read the conference call transcript. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional investors include Bridge City Capital LLC (0.28%), Rhumbline Advisers (0.19%), GAMMA Investing LLC (0.17%) and Hennion & Walsh Asset Management Inc. (0.15%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, John C Jacobs, Sandip Kapadia, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings2/25/2025Today4/24/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$53.33 High Stock Price Target$70.00 Low Stock Price Target$40.00 Potential Upside/Downside+81.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.51 Trailing P/E Ratio13.93 Forward P/E Ratio12.10 P/E Growth0.47Net Income$128.85 million Net Margins17.98% Pretax Margin25.71% Return on Equity23.16% Return on Assets14.24% Debt Debt-to-Equity Ratio0.28 Current Ratio3.24 Quick Ratio3.20 Sales & Book Value Annual Sales$714.73 million Price / Sales2.36 Cash Flow$2.20 per share Price / Cash Flow13.38 Book Value$7.97 per share Price / Book3.69Miscellaneous Outstanding Shares57,346,000Free Float39,465,000Market Cap$1.69 billion OptionableOptionable Beta0.80 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:HRMY) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.